Leap Therapeutics Inc. has released its financial results for the second quarter of 2025. The company reported a net loss of $16.6 million, an improvement from the $20.4 million net loss experienced during the same period in 2024. This decrease in net loss was largely attributed to a reduction in research and development and general and administrative expenses, although it was partially offset by restructuring charges due to a workforce reduction. Research and development expenses for the second quarter of 2025 were $10.5 million, down from $17.9 million in the second quarter of 2024. This $7.4 million decrease resulted from lower clinical trial costs, payroll and headcount-related expenses, manufacturing costs, and stock-based compensation expenses. Significant business updates include the company's strategic restructuring, which involved a 75% workforce reduction aimed at preserving capital. Additionally, the Board of Directors has initiated a process to explore strategic alternatives to maximize shareholder value, including potential sales or partnerships for its therapies sirexatamab and FL-501. Raymond James & Associates, Inc. has been engaged as the exclusive financial advisor to assist in this strategic evaluation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.